Eagle Pharmaceuticals Inc (NAS:EGRX)
$ 3.65 -0.16 (-4.2%) Market Cap: 47.30 Mil Enterprise Value: 105.76 Mil PE Ratio: 4.01 PB Ratio: 0.19 GF Score: 62/100

Q4 2022 Eagle Pharmaceuticals Inc Earnings Call Transcript

Mar 13, 2023 / 12:30PM GMT
Release Date Price: $25.51 (+1.80%)
Operator

Good morning, everyone. My name is Todd, and I'll be your conference operator. At this time, I'd like to welcome everyone to Eagle Pharmaceuticals Fourth Quarter and Full Year 2022 financial results. (Operator Instructions) As a reminder, this conference call is being recorded today, March 13, 2022. It is now my pleasure to turn the floor over to Ms. Lisa Wilson, Investor Relations for Eagle Pharmaceuticals. Please go ahead.

Lisa Wilson

Thank you, Tom. Welcome to Eagle Pharmaceuticals Fourth Quarter and Full Year 2022 Earnings Call. This is Lisa Wilson, Investor Relations for Eagle Pharmaceuticals. With me on today's call are Eagle's President and Chief Executive Officer, Scott Tarriff; Chief Financial Officer; Brian Cahill, and Vice President of Medical Affairs; Dr. Mike Greenberg.

This morning, Eagle issued a press release detailing its financial results for the 3 months and full year ended December 31, 2022. This press release and a webcast of this call can be accessed through the Investors section of the Eagle website at eagleus.com.

Before we

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot